grant | 2025 - 2026
Functional and Transcriptomic analysis of Antisense Oligomer Mediated Modulation of C9ORF72 variant expression
Perron Institute for Neurological and Translational Science
Grant no. 22763.
grant | 2024 - 2025
Initial studies of how well a potential new drug for treating motor neuron disease gets to where it needs to act in a living system and to learn how this distribution affects safety and effectiveness
Western Australian Department of Health
Grant no. 22395.
grant | 2023 - 2023
Modulation of the autophagy pathway to clear TDP-43 aggregation as a therapeutic strategy for ALS and FTLD
Perron Institute for Neurological and Translational Science
Grant no. 21369.
grant | 2022 - 2024
Modulation of the Autophagy Pathway to treat Neurogenerative Diseases
General
Grant no. 21102.
grant | 2020 - 2021
Antisense oligonucleotide targeting of p62-mediated TDP-43 pathology as a treatment for amyotrophic lateral sclerosis
General
Grant no. 19825.
grant | 2020 - 2022
Modulation of accessory pathways to ameliorate neurodegenerative disease
General
Grant no. 19832.
grant | 2020 - 2023
Pre-clinical development of a SOD1 genetic therapy in sporadic ALS: enabling investigational new drug submission
General
Grant no. 19597.
grant | 2020 - 2021
Risk genes in sporadic Inclusion Body Myositis (IBM)
General
Grant no. 19819.
grant | 2020 - 2021
Role of NEAT1 gene in ALS and IBM
General
Grant no. 19826.
grant | 2020 - 2021
Validation of motor neuron disease patient olfactory neural stem cells as a drug evaluation platform
General
Grant no. 19968.
grant | 2020 - 2021
WA MND Research Consortium:
General
Grant no. 19668.
grant | 2019 - 2020
Antisense oligonucleotide mediated knockdown of Ataxin-2: a potential therapy for amyotrophic lateral sclerosis.
General
Grant no. 19220.
grant | 2019 - 2022
Perron Sponsored Position - Dr Ianthe Pitout
General
Grant no. 18874.
grant | 2016 - 2017
Ianthe Pitout - TEAM Spencer Muscular Dystrophy WA PhD Scholarship Program for 2016
General
Grant no. 17001.